Lancet, PLoS Publish Studies on Antiretroviral Therapy
- "Mortality of HIV-1-Infected Patients in the First Year of Antiretroviral Therapy: Comparison Between Low-Income and High-Income Countries," Lancet: Matthias Egger of the Department of Social and Preventive Medicine at the University of Bern, Switzerland, and colleagues looked at the outcomes of the first year of highly active antiretroviral therapy in HIV-positive people in low- and high-income countries. The study finds that people in low-income countries had a higher mortality rate during the first months of HAART than people in high-income countries. The study says a more "[t]imely diagnosis" and a better "assessment of treatment eligibility" as well as no-cost HAART might help decrease the mortality rate (Egger et al., Lancet, 3/11).
- "Modeling the Impact of Antiretroviral Use in Resource-Poor Settings," PLoS Medicine: Rebecca Baggaley, Geoff Garnett and Neil Ferguson of the Department of Infectious Disease Epidemiology at the Imperial College London found that antiretroviral use cannot be used as the sole HIV prevention strategy in any setting, including resource-poor settings. According to the study, "Counseling of patients to promote safe sexual practices is essential and must aim to effect long-term change" (Baggaley et al., PLoS Medicine, April 2006).
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.